| Yu, Bo |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Active, not recruiting | N/A | 2059 | RoW | Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System | Boston Scientific Corporation | Coronary Artery Disease | 12/20 | 02/25 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
| Active, not recruiting | N/A | 347 | RoW | dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) | Harbin Medical University, Shenzhen Salubris Pharmaceuticals Co., Ltd., Beijing Luhe Hospital, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First Affiliated Hospital of Dalian Medical University, Shanxi Cardiovascular Hospital, Second Hospital of Shanxi Medical University, Hebei General Hospital, General Hospital of Ningxia Medical University, Sichuan Provincial People's Hospital, Affiliated Hospital of Jiangsu University, Xiamen Cardiovascular Hospital, Xiamen University, Shenzhen Sun Yat-sen Cardiovascular Hospital, LanZhou University, Sir Run Run Shaw Hospital, Wuhan Asia Heart Hospital | ST-segment Elevation Myocardial Infarction | 02/22 | 03/23 | | |
EMPOWER, NCT04289480: Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 164 | RoW | ENTERPRISE 2 device | Medos International SARL, Johnson & Johnson Medical (Shanghai) Ltd. | Intracranial Aneurysm | 04/22 | 01/27 | | |
NCT05015699: A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI |
|
|
| Withdrawn | N/A | 285 | NA | HT Supreme | Sino Medical Sciences Technology Inc., The Second Affiliated Hospital of Harbin Medical University | Coronary Artery Disease | 09/22 | 07/25 | | |
COOPERATION, NCT04912518: Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction |
|
|
| Recruiting | N/A | 250 | RoW | Dexmedetomidine (DEX), Placebo (Saline) | Harbin Medical University, Yangtze River Pharmaceutical Group Co., Ltd. | ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection | 12/24 | 12/25 | | |
NCT05818098: Coronary Intravascular Lithotripsy System in Patients With Coronary Artery Calcification (VIGOUR) |
|
|
| Recruiting | N/A | 189 | RoW | Intravascular Lithotripsy System of Shanghai MicroPort Rhythm | Shanghai MicroPort Rhythm MedTech Co., Ltd. | Coronary Artery Calcification | 09/23 | 03/24 | | |
NCT05795829: Ultrasound Ablation for Essential Hypertension（FIM） |
|
|
| Recruiting | N/A | 10 | RoW | disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument | Lepu Medical Technology (Beijing) Co., Ltd. | Uncontrolled Essential Hypertension | 12/23 | 02/24 | | |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
| Recruiting | N/A | 180 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 06/26 | 06/26 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Zhang, Jianguo |
NCT04244513: Deep Brain Stimulation Treatment for Chorea in Huntington's Disease |
|
|
| Recruiting | N/A | 40 | RoW | Deep brain stimulation | Beijing Municipal Administration of Hospitals, Medtronic | Huntington Disease, Deep Brain Stimulation | 06/23 | 12/23 | | |
NCT05993117: Rechargeable Implantable Vagus Nerve Stimulation System for Drug-Refractory Epilepsy |
|
|
| Recruiting | N/A | 20 | RoW | G114R VNS system | Beijing Pins Medical Co., Ltd, Peking University First Hospital, Beijing Tiantan Hospital | Drug-Refractory Epilepsy | 06/24 | 12/24 | | |
NCT02251808: Satisfaction Survey on PINS Stimulator System for Patients With Parkinson's Disease |
|
|
| Recruiting | N/A | 612 | RoW | | Beijing Pins Medical Co., Ltd, Beijing Tiantan Hospital | Parkinson's Disease | 09/24 | 09/24 | | |
NCT06498934: Deep Brain Stimulation of the Dentate Nucleus for Motor Rehabilitation After Stroke |
|
|
| Not yet recruiting | N/A | 52 | RoW | deep brain stimulation, Rehabilitation | Beijing Municipal Administration of Hospitals, Beijing Pins Medical Co., Ltd | Stroke, Upper Extremity Paresis | 12/26 | 12/27 | | |
| Recruiting | N/A | 110 | RoW | STN-DBS, subthalamic necleus-deep brain stimulation, GPi-DBS, globus pallidus internus-deep brain stimulation | Beijing Tiantan Hospital, Peking Union Medical College Hospital, Peking University People's Hospital, Civil Aviation General Hospital, Chinese PLA General Hospital, Beijing Pins Medical Co., Ltd | Craniofacial Dystonia, Deep Brain Stimulation | 09/24 | 09/24 | | |
| Chen, Yu |
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
|
|
| Recruiting | 2 | 58 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 06/22 | 09/22 | | |
NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation |
|
|
| Recruiting | 2 | 30 | RoW | HLX208 | Shanghai Henlius Biotech | Advanced Melanoma | 08/23 | 08/24 | | |
NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | QLF31907 | Qilu Pharmaceutical Co., Ltd. | Melanoma, Urothelial Carcinoma | 10/23 | 07/24 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT05664139: Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma |
|
|
| Not yet recruiting | 2 | 30 | NA | Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel | Fujian Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd., SunWay Biotech Co., LTD. | Malignant Melanoma, Liver Metastases | 12/24 | 12/25 | | |
NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 120 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 06/25 | 07/26 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 42 | RoW | T3011 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Melanoma | 09/25 | 09/25 | | |
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 63 | RoW | SPH4336, Cadonilimab | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 05/25 | 12/25 | | |
| Recruiting | 1 | 189 | RoW | KY-0118 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Neoplasms, Neoplasms by Histologic Type | 12/25 | 12/25 | | |
NCT05989958: The Safety and Tolerability Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure |
|
|
| Recruiting | 1 | 12 | NA | HepaCure | Hexaell Biotech Co., Ltd. | Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis | 09/24 | 09/24 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Recruiting | 1 | 144 | US, RoW | ADRX-0706 | Adcentrx Therapeutics | Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer | 09/25 | 12/26 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
| Shi, Yan |
NCT06209385: A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 157 | RoW | YZJ-5053 tablets, SHY-1901 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Solid Tumor | 10/27 | 01/28 | | |
NCT05169697: A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors |
|
|
| Completed | 1 | 6 | RoW | A:YH002+YH001, B:YH002+YH001, YH002+YH001 | Eucure (Beijing) Biopharma Co., Ltd | Advanced Solid Tumor | 07/23 | 07/23 | | |
| Wang, Lihua |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| TIAN, YE |
CSPPT2-TT, NCT04974151: China Stroke Primary Prevention Trial 2 for Participants with Hypertension and MTHFR 677 TT Genotype |
|
|
| Recruiting | 4 | 24000 | RoW | Amlodipine besylate, Amlodipine, Amlodipine besylate And Folic Acid, Amlodipine Folic Acid, Anye, 5-methyltetrahydrofolate (5-MTHF), 5-MTHF, Amlodipine placebo, Amlodipine (dummy), Amlodipine folic acid placebo, Amlodipine folic acid (dummy), 5-MTHF Placebos, 5-MTHF (dummy) | Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD | Hypertension, MTHFR 677 TT Genotype | 06/29 | 06/29 | | |
CSPPT2-CC/CT, NCT04974138: China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype |
|
|
| Recruiting | 4 | 32000 | RoW | Amlodipine besylate, Amlodipine, Amlodipine besylate and folic acid, Amlodipine folic acid, Anye, Amlodipine placebos, Amlodipine (dummy), Amlodipine-folic acid placebos, Amlodipine-folic acid (dummy) | Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD | Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL) | 06/29 | 06/29 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
| Tu, Ping |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
| Pan, Ling |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
| Recruiting | 2 | 105 | RoW | TQ05105 tablets, Hydroxycarbamide tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Moderate and High Risk Myelofibrosis | 03/23 | 09/23 | | |
| Xu, Jianguo |
| Recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
| Cao, Muhua |
FISSTEMI, NCT04663932: Primary FIbrinolysis and Secondary STenting Versus immEdiate Stenting in ST-segment Elevation Myocardial Infarction |
|
|
| Recruiting | N/A | 240 | RoW | immediate stenting group(one-step strategy), Immediate Angioplasty, deferred stenting group (two-step strategy), Delayed angioplasty | Harbin Medical University, Tasly Pharmaceuticals, Inc. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 03/22 | 03/23 | | |
| Jiao, Jundong |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
| Yan, Jinglong |
| No trials found |
| Wang, Guiyu |
| No trials found |
